Fig. 5: Recombinant CHI3L1 (rCHI3L1) ameliorates Con A-induced hepatitis.

A Representative flow cytometry plots for analysing proliferation of CD3⁺ T cells labelled with CFSE treated with rCHI3L1 in indicated conditions. PBS was used as a control. B Quantification of flow cytometry analysis for proliferation of CD3⁺ T cells labelled with CFSE in PBS (control) or rCHI3L1 (100 ng/mL) treated group (n = 3 biological replicates). C–F Representative plots (C–D) and quantification (E–F) of flow cytometry analysis for CD25 and CD69 expression in CD3⁺ T cells treated with control (PBS) or rCHI3L1 (100 ng/mL) (n = 3 biological replicates). G–J Representative plots (G–H) and quantification (I–J) of flow cytometry analysis for IFN-γ and TNF-α expression in CD3⁺ T cells treated with control (PBS) or rCHI3L1 (100 ng/mL) (n = 3 biological replicates). K Representative H&E staining photographs of liver tissues 24 h after Con A administration in control (PBS) and rCHI3L1 (500 ng) treated groups. Scale bar = 100 μm. L Serum ALT and AST (M) levels 24 h after Con A treatment in indicated groups (n = 4–7 mice per group). Data in (B), (E), (F), (I), (J), (L), and (M) are shown as mean ± SD with indicated significance (*p < 0.05, **p < 0.01).